Cannabis and Heart Health

Key Takeaways

• The short-term effects are well established. Inhaled THC raises heart rate within about thirty minutes and returns to baseline within three to four hours, and it can cause blood pressure to drop on standing [1, 2].
• The long-term picture is not settled. Two studies published in the same year reported heart attack risks for cannabis that differ by nearly fivefold [12, 13].
• Tobacco is the single biggest reason the studies disagree. In the foundational study, 68% of cannabis users also smoked cigarettes, against 32% of nonusers [3].
• Many of the widely reported studies are snapshots that cannot tell whether the heart problem came before or after the cannabis use [4, 13].
• Cannabis products have changed faster than the research measuring them. Average THC content roughly tripled between 1995 and 2014 [10].

---

What Is Already Settled

One part of this field is clear, and it is the short-term part.

In a controlled trial, seventeen adults who had not used cannabis in at least a month received measured doses of THC, both smoked and vaporized, on separate days [1]. Heart rate and blood THC peaked within thirty minutes and returned to normal within three to four hours. The same dose delivered noticeably more THC into the blood when vaporized than when smoked, so how a product is used changes the exposure even when the labeled amount is identical.

The 2020 American Heart Association scientific statement describes the same acute picture: a dose-dependent rise in heart rate, higher blood pressure while lying down, and a drop in blood pressure on standing [2]. None of that is in dispute. Cannabis & the Cardiovascular System covers how these acute effects fit into circulation more broadly.

What follows concerns a different question. Not the next few hours, but what happens across years to rates of heart attack and stroke in whole populations. That question has produced a contradictory body of research, and the contradictions have identifiable causes.

Why the Numbers Are So Far Apart

In 2025, one study of hospital records reported that cannabis users had roughly six times the rate of heart attack as nonusers [12]. The same year, a pooled analysis of twenty-four studies covering about 200 million people reported an increase of 29% [13].

Both are real studies. They differ mainly in who ends up counted as a cannabis user.

Consider estimating how many households own a ladder by counting only those that have mentioned a ladder to an emergency room doctor. Every household in that count really does own one, so the data are accurate as far as they go. But ladder ownership will look terrifying, because the thing that gets a ladder written into a medical record is usually the fall.

The hospital-records study works the same way. A patient entered the cannabis group only if a clinician typed a cannabis diagnosis code into the chart, which tends to happen when someone arrives acutely unwell. Everyone whose chart says nothing about cannabis, including plenty of actual users, went into the comparison group.

The pooled analysis has the opposite weakness. Seventeen of its twenty-four studies were snapshots taken at a single moment, which cannot establish whether the heart attack came before or after the cannabis use [13]. Averaging seventeen studies with that limitation produces a tidy number carrying the same flaw.

Longer follow-up can also change the answer. When researchers tracked heart attack survivors for eighteen years, cannabis use before the heart attack was linked to a 29% higher death rate, but the result was not statistically significant, and the confidence interval was wide enough to include no effect at all. An earlier analysis of the same cohort, at a median of 3.8 years, had reported a clearly increased mortality rate [5]. The longer the follow-up, the weaker the signal became.

The Tobacco Problem

Most people who use cannabis regularly have also smoked tobacco, and tobacco is among the best-documented causes of heart attack and stroke that exists. Separating the two is the central difficulty in this field.

The overlap is not subtle. In the 2001 study that first linked cannabis to heart attack, 68% of cannabis users were current cigarette smokers, against 32% of nonusers [3].

Where researchers report results both before and after accounting for tobacco, the numbers move. An Australian survey found cannabis users had 3.3 times the rate of stroke or transient ischemic attack when only age was accounted for. Including tobacco and other stroke risk factors dropped that to 2.3 [7]. A Canadian study of more than 1.2 million women found a clear rise in cardiovascular hospitalization when cannabis was combined with other substances, but the estimate for cannabis alone was not statistically significant [8].

The most rigorous test comes from Sweden, where 49,321 men were surveyed at ages eighteen to twenty and tracked through national health registries for roughly forty years [6]. Among men who had used cannabis more than fifty times, there was no statistically significant increase in stroke. In the same group of men, smoking twenty or more cigarettes a day was associated with five times the rate of stroke before age forty-five.

One recent study got around the problem by design instead of statistics, recruiting only people who did not smoke tobacco, did not vape, and had little secondhand exposure [9]. Both cannabis smokers and THC edible users showed reduced blood vessel function compared with nonusers. It included only 55 people and measured a laboratory marker, not actual heart attacks, so it is a starting point and not an answer. It does show the tobacco question can be handled at the recruitment stage.

Cannabis Today Is Not Cannabis in 1995

A study that followed people using cannabis in the early 1990s is not measuring the same product sold today.

Analysis of nearly 39,000 seized samples found average THC content rose from about 4% in 1995 to about 12% by 2014, while CBD content fell [10]. Concentrates, vape cartridges, and edibles that barely existed in the older studies now make up a substantial share of the market.

There is also no standard dose. Alcohol research has the standard drink, which lets a researcher compare a beer to a glass of wine. Cannabis has no equivalent in general use, though a standard THC unit of 5 milligrams has been proposed [11]. Until something like it is adopted, a survey asking how many days a month someone used cannabis captures nothing about how much THC was actually taken in.

What Genetic Studies Add

One approach sidesteps confounding entirely. Researchers can use genetic variants linked to cannabis use as a stand-in for the exposure, since genes are fixed at birth and cannot be influenced by whether someone later develops heart disease.

The largest such analysis used 65 genetic variants and found no causal effect of cannabis on coronary artery disease or ischemic stroke [15]. Two other independent analyses reached broadly similar conclusions.

These are not the final word either. They capture a genetic tendency to try cannabis at some point, not how much, how strong, how it was used, or when, and they cannot detect a short-term trigger effect. What they establish is that the associations seen in survey research do not reappear when exposure is measured this way, and that gap needs explaining.

One Finding That Keeps Recurring

Not everything here is contradictory. Across reviews, the most consistent signal is for heart rhythm disturbances, not heart attack [16].

A Danish study using national prescription registries followed 5,391 chronic pain patients who started medical cannabis and compared them with 26,941 matched patients who did not [14]. New heart rhythm problems occurred in 0.8% of the cannabis group within six months, against 0.4% of the comparison group. There was no significant difference in acute coronary events.

The absolute numbers are small, and the pattern weakened at one year, which could reflect a real early effect or the extra medical attention that comes with starting any new prescription. But this is where independent studies point the same direction most often.

Frequently Asked Questions

Is cannabis bad for my heart?

The research does not settle that question yet, and the reasons are specific. Studies disagree because they define cannabis use differently, because most cannabis users also use tobacco, and because many designs cannot establish which came first. What is known is the short-term effect: your heart rate will rise for a few hours after inhaling THC, and your blood pressure may drop when you stand up. If you have existing heart disease, that acute effect is the concrete thing your cardiologist can reason about.

Does it matter whether I smoke it or eat it?

Route changes how much THC reaches your bloodstream and how fast [1]. In the study that recruited out tobacco users, both smokers and edible users showed reduced blood vessel function, though the underlying mechanism appeared different between them [9]. Edibles avoid inhaled combustion products, a real difference, but current evidence does not support treating them as cardiovascularly neutral.

I have a heart condition. What should I tell my doctor?

Tell them what you use, how you use it, roughly how much, and how often. Route and frequency matter more than a yes-or-no answer about cannabis, and most of the uncertainty in the research comes from exactly the details that get left out. If you take cardiac medications, mention it, since interactions are a separate question from the risk discussed here and are covered in Cannabis and Prescription Drug Interactions.

Should I stop using cannabis until the research is clearer?

That is not a question the current evidence answers, and anyone who tells you otherwise is going beyond what the studies support. What the evidence does establish is that if you also smoke tobacco, that is the exposure with the strongest and least ambiguous link to heart attack and stroke, and it is the one where stopping has clearly documented benefit [3, 6].

Why do new studies keep reaching opposite conclusions?

Because they measure different things under the same word. A hospital records study, a phone survey, a prescription registry, and a genetic analysis all describe something called cannabis use, but the people captured by each method are not the same people.

Bottom Line

The acute effects of inhaled THC on heart rate and blood pressure are well documented. Whether regular use changes long-term risk of heart attack or stroke is unresolved, and the disagreement in the published research comes from measurable differences in study design, not from any mystery about cannabis itself.

That means no single risk figure deserves much weight on its own, in either direction. The 2025 pooled analysis reached general audiences through headlines about marijuana dramatically increasing the risk of dying from heart attack and stroke, without mentioning that seventeen of its twenty-four studies were snapshots. The reverse compression is equally available and simply happens less often: a forty-year Swedish cohort and three genetic analyses could support a headline announcing that cannabis carries no cardiovascular risk, and it would misrepresent its sources exactly as much.

What deserves weight is the pattern. Findings that survive tobacco adjustment, designs that establish which event came first, and results that repeat across independent research groups. By that standard the acute effects are solid, the heart rhythm signal is the most consistent long-term finding, and the heart attack question remains open. For someone with cardiac disease who uses cannabis, that is a conversation for a cardiologist, not a question to settle from a headline.

The full evidence base behind this article, including the design of each study and the confounder each one leaves standing, is set out in the Hytiva Research companion, Cardiovascular Safety of Cannabis: Why the Evidence Disagrees With Itself.